Further investigation and validation of the methylation dependent regulation of the 14q32 locus in CLL, perhaps using long read technologies that offer high resolution DNA sequencing, methylation status and phasing of methylated CpGs across the locus would highlight the potential for demethylating agents to relieve repression of 14q32 miRNA and MEG3 in high risk CLL subsets. The gene discussed is MEG3; the disease is B-cell chronic lymphocytic leukemia.